Edition:
India

Spectrum Pharmaceuticals Inc (SPPI.OQ)

SPPI.OQ on NASDAQ Stock Exchange Global Select Market

19.03USD
2:29am IST
Change (% chg)

$0.20 (+1.06%)
Prev Close
$18.83
Open
$18.77
Day's High
$19.08
Day's Low
$18.58
Volume
193,572
Avg. Vol
480,120
52-wk High
$21.95
52-wk Low
$4.33

Chart for

About

Spectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved... (more)

Overall

Beta: 1.56
Market Cap(Mil.): $1,341.42
Shares Outstanding(Mil.): 93.94
Dividend: --
Yield (%): --

Financials

BRIEF-Spectrum Pharmaceuticals Says Expect To File A Registration Application (Bla) With FDA For Rolontis

* SPECTRUM PHARMACEUTICALS SAYS EXPECT TO FILE A REGISTRATION APPLICATION (BLA) WITH FDA FOR ROLONTIS IN Q4 2018 - SEC FILING Source text for Eikon: (http://bit.ly/2EmWf09) Further company coverage:

08 Jan 2018

BRIEF-Spectrum Pharmaceuticals reports Q3 non-GAAP loss per share of $0.11

* Spectrum Pharmaceuticals reports third quarter 2017 financial results and pipeline update

03 Nov 2017

BRIEF-Spectrum Pharmaceuticals announces initiation of a multicenter phase 2 trial of poziotinib in non-small cell lung cancer patients with Exon 20 insertion mutation in EGFR or HER2

* Spectrum Pharmaceuticals announces initiation of a multicenter phase 2 trial of poziotinib in non-small cell lung cancer (NSCLC) patients with Exon 20 insertion mutation in EGFR or HER2 Source text for Eikon: Further company coverage:

30 Oct 2017

BRIEF-Spectrum Pharma to exchange $69.5 million in principal amount of its 2.75% convertible senior notes due 2018 for common stock and cash

* Spectrum Pharmaceuticals announces agreements to exchange $69.5 million in principal amount of its 2.75% convertible senior notes due 2018 for common stock and cash

10 Oct 2017

BRIEF-Spectrum Pharmaceuticals provides update on at-the-market facility

* Spectrum Pharmaceuticals Inc provides update on at-the-market facility

29 Sep 2017

BRIEF-Spectrum Pharma starts phase 3 qapzola trial

* Spectrum pharmaceuticals announces initiation of the registrational phase 3 trial of qapzola™ (apaziquone) in patients with non-muscle invasive bladder cancer (nmibc)

14 Aug 2017

BRIEF-Spectrum Pharma enters into an at market issuance sales agreement

* Spectrum Pharmaceuticals Inc - on August 4, 2017, co entered into an at market issuance sales agreement - sec filing

05 Aug 2017

BRIEF-Spectrum Pharmaceuticals Q2 loss per share $0.26

* Spectrum Pharmaceuticals reports second quarter 2017 financial results and pipeline update

04 Aug 2017

BRIEF-Spectrum Pharmaceuticals announces ‍enrollment in Rolontis phase 3 advance pivotal study​

* Spectrum Pharmaceuticals Inc - ‍enrollment with 405 patients randomized in rolontis phase 3 advance pivotal study​

01 Aug 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $147.36 +0.44
Pfizer Inc. (PFE.N) $36.94 -0.05
Novartis AG (NOVN.S) CHF83.38 +0.48
Merck & Co., Inc. (MRK.N) $61.28 +0.15
Roche Holding Ltd. (ROG.S) CHF234.50 +1.30
Roche Holding Ltd. (RO.S) CHF237.80 +1.00
Abbott Laboratories (ABT.N) $59.31 +0.24
Bayer AG (BAYGn.DE) €104.08 +0.60
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €72.95 +0.58

Earnings vs. Estimates